SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Nanalysis Scientific Corp. (NSCIF) , forward earnings yield 32.05%. PEG 0.05 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 3.1
- PEG Ratio 0.05 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 22/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NSCIF
Valuation Multiples
P/E (TTM)0.0
Forward P/E3.1
PEG Ratio0.05
Forward PEG0.05
P/B Ratio0.00
P/S Ratio0.23
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.12
Forward EPS (Est.)$0.03
Book Value / Share$0.00
Revenue / Share$0.41
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield32.05%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-0.03 |
$5.25M |
$-25.28K |
-0.5% |
| 2017 |
$-0.17 |
$7.67M |
$-172.11K |
-2.2% |
| 2018 |
$0.00 |
$8.38M |
$74K |
0.9% |
| 2019 |
$-0.03 |
$8.36M |
$-1.66M |
-19.8% |
| 2020 |
$-0.06 |
$7.87M |
$-3.68M |
-46.7% |
| 2021 |
$-0.03 |
$16.04M |
$-1.77M |
-11% |
| 2022 |
$-0.11 |
$24.82M |
$-9.92M |
-39.9% |
| 2023 |
$-0.16 |
$28.47M |
$-16.78M |
-59% |
| 2024 |
$-0.12 |
$45.5M |
$-13.61M |
-29.9% |
